퍼스펙티브 테라퓨틱스(CATX)는 NYSE MKT에 상장된 Healthcare · Medical Devices 기업입니다. 현재가 $2.84 (-1.39%), 시가총액 $0.44B, 52주 최저~최고 $2.05 ~ $5.65.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV
퍼스펙티브 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
퍼스펙티브 테라퓨틱스의 현재 주가는 $2.84 (-1.39%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
퍼스펙티브 테라퓨틱스의 시가총액은 약 $0.44B입니다.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and d